Design of Nanostructured Lipid Carriers Ubiquinone-10 for Transdermal Treatment

Main Authors: Fatchur Rochman, M, Isnaeni, Isnaeni, Hendradi, Esti
Format: Article PeerReviewed Book
Bahasa: eng
Terbitan: International Society for Science and Nature , 2018
Subjects:
Online Access: http://repository.unair.ac.id/86214/5/C-7%20fix.pdf
http://repository.unair.ac.id/86214/1/Result%20Bukti%20C-07.pdf
http://repository.unair.ac.id/86214/4/Rev%20C-7.pdf
http://repository.unair.ac.id/86214/
http://impactfactor.org/PDF/IJDDT/8/IJDDT,Vol8,Issue3,Article1.pdf
Daftar Isi:
  • Ubiquinone-10 is a cellular endogenous antioxidant that resides in the epidermal layer. Ubiquinone-10 can increase the production of basal membrane components, fibroblast proliferation and protect cells from oxidative damage, so with increasing age, the amount of Ubiquinone-10 body will decrease. Bioavailability and permeability of Ubiquinone-10 are very low, thus affecting the potential efficacy and absorption in Ubiquinone-10. The preparation of Ubiquinone-10 formulation needs to be done to obtain products that have good bioavailability. Nanostructured Lipid Carrier (NLCs) is a modification of the SLN system, consisting of a certain amount of lipid matrix and liquid lipids. Mixtures of solid lipids and liquid lipids can provide space for drug trapping. The system will remain in solid form by controlling the concentration of the liquid lipids to be added into the formula so that the drug release process can be controlled.